Lv1
10 积分 2022-07-15 加入
Long-term Follow-up of Zimberelimab in Relapsed or Refractory Classic Hodgkin Lymphoma: Insights from the Phase Ⅱ YH-S001-04 Clinical Trial
1天前
待确认
Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies
4天前
已完结
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review
4天前
已完结
Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer Promising Clinical Target or Only a Marker?
5天前
已完结
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
6天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
6天前
已完结
Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR -Mutated Non–Small Cell Lung Cancer: Old or New Regimen?
6天前
已完结
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial
1个月前
已完结
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
1个月前
已完结
Reactivation of pemphigus by varicella zoster virus after anti‐CD20 treatment
2个月前
已完结
皖公网安备34019202002308
